Home/IPOs/SUDEEPPHRM

SUDEEPPHRM IPO

Sudeep Pharma Limited

IPO Doc

Start Date21-11-2025

Application Timing10am-5pm

Price Range₹563 - ₹593

Min Qty25

Min. Investment₹14075

Listing Date28-11-2025

Close Date25-11-2025

About Sudeep Pharma Limited

Sudeep Pharma Limited, incorporated in 1989, is a leading manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients. The company serves customers across more than 100 countries, supported by six manufacturing facilities with a total installed capacity of 50,000 MT.

Its product portfolio includes calcium, iron, zinc, magnesium, sodium, and potassium mineral salts, along with specialty ingredients and triturates. Sudeep Pharma supplies over 200 products to global clients in the pharmaceutical, food, and nutrition industries.

The company has strong in-house R&D capabilities, equipped with advanced labs and pilot-scale facilities focused on innovation in mineral salts and excipients. As of December 31, 2024, the company employed 704 permanent employees.

Why To Invest in Sudeep Pharma Limited

Strong Global Presence : The company exports to more than 100 countries and maintains long-term relationships with leading global pharmaceutical and nutrition brands.

Diverse Product Portfolio : With over 200 products across excipients, food-grade minerals, and specialty ingredients, the company benefits from multiple revenue streams.

High Entry Barrier Industry : Pharma excipients and specialty mineral ingredients require stringent regulatory approvals, creating natural entry barriers and supporting sustainable growth.

Robust Financial Performance : Revenue and PAT have shown consistent growth. In FY 2025, PAT increased to Rs. 138.69 Cr, supported by healthy margins such as EBITDA margin of 39.70%.

Capacity Expansion via IPO Funds : The IPO proceeds will be used for machinery procurement and capacity enhancement, supporting future growth and operational efficiency.

Strong Promoter Background : Promoters hold extensive experience, and even post-issue they will retain significant ownership at 76.15%.

Financial Table

Period Ended	30 Jun 2025	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	922.26	717.17	513.87	420.11
Total Income	130.08	511.33	465.38	438.26
Profit After Tax	31.27	138.69	133.15	62.32
EBITDA	48.57	199.28	187.76	98.64
NET Worth	688.32	497.53	359.07	226.29
Reserves and Surplus	668.52	481.11	354.59	221.88
Total Borrowing	135.97	135.25	75.03	82.26

Strengths And Risks

Market Leadership in Pharma Excipients: Sudeep Pharma holds a strong leadership position in the pharmaceutical excipients and mineral-based ingredient segment, operating in an industry with high entry barriers and strict regulatory requirements.

Diversified Global Customer Base: The company serves clients across more than 100 countries, maintaining long-term relationships with major pharmaceutical, food, and nutrition brands. This global reach reduces dependency on any single market.

Advanced and Compliant Manufacturing Facilities: Its six manufacturing units are equipped with modern technology and adhere to regulatory standards, ensuring consistent product quality and scalable operations.

Strong Research and Development Capabilities: Sudeep Pharma has dedicated R&D labs and pilot-scale facilities focused on innovation in mineral salts, excipients, and specialty ingredients, enabling continuous product development.

Consistent Financial Growth: The company has demonstrated stable financial performance with healthy profitability. Strong EBITDA margins and growing net worth reflect a solid financial foundation.

Dependence on Global Pharma and Nutrition Sectors: A slowdown in the pharmaceutical, food, or nutrition industries may directly impact demand for the company’s products and overall revenue growth.

Raw Material Price Volatility: The company relies on key mineral-based raw materials, which may experience price fluctuations. This can affect cost structures and margins if not managed effectively.

High Regulatory Dependence: Operating in a heavily regulated sector requires continuous compliance. Any failure to meet regulatory standards can lead to operational disruptions or penalties.

Premium Valuation: The IPO is priced at a higher valuation, with a post-issue P/E of 53.55x. This may be considered expensive when compared to industry peers.

Exposure to Foreign Exchange Movements: With exports to 100+ countries, the company is exposed to currency risks. Fluctuations in foreign exchange rates may impact profitability.

FAQs

What is the issue size of the Sudeep Pharma IPO? +

What does the IPO consist of? +

What is the Sudeep Pharma IPO price band? +

What is the lot size for retail investors? +

What is the minimum investment required for retail investors? +

E-IPO

Get In On The Action EarlyBuy cheap, earn big. Discover IPOs with the highest growth potential early and invest now through Rupeezy to earn big in the future.

Explore Other Products

Rupeezy AppAdvanced charts, advanced Option Chain, instant pay-in & pay-out,margin .Learn More

Rupeezy <> TradingViewEnjoy top-class trading experience enhanced by advanced TradingView charts.Learn More

DockPortfolio analysis, pledge holdings, apply in IPOs & download reports Learn More

3rd Floor, Incubex INR4, 777c, 100 Feet Rd, HAL 2nd Stage, Indiranagar, Bengaluru, Karnataka 560038

0755-4268599, 0755-6693322

support@rupeezy.in

Download the Rupeezy App now

Products

NFO

Platform

Rupeezy <> TradingView

Partner App (MFD)

Partner Login

Features

Iceberg

MF Lab

Smart Explore

T+5

Business

Become an MFD

Become an AP

Authorized Person Lists

Help

Company

Astha Credit & Securities Pvt Ltd NSE, BSE & MCX SEBI Reg No:

INZ000187932

Membership ID:

NSE - 12227 BSE-6844 MCX - 40000 NSDL-IN303420 CDSL-94500

CIN:

U65929MP2003PTC016241

SEBI Depository Participant Reg No:

IN-DP-611-2021

For any grievance contact:

grievance@rupeezy.in
0755-4268599

For cyber attack incident reporting:

gyanesh@rupeezy.in
9669695615

SEBI RA Registration:

INH000013332

AMFI Registration:

ARN-35911

Attention Investors:

Beware of fixed/guaranteed/regular returns/ capital protection schemes. Brokers or their authorized persons or any of their associates are not authorized to offer fixed/guaranteed/regular returns/ capital protection on your investment or authorized to enter into any loan agreement with you to pay interest on the funds offered by you. Please note that in case of default of a member claim for funds or securities given to the broker under any arrangement/ agreement of indicative return will not be accepted by the relevant Committee of the Exchange as per the approved norms.
Do not keep funds idle with the Stock Broker. Please note that your stock broker has to return the credit balance lying with them, within three working days in case you have not done any transaction within last 30 calendar days. Please note that in case of default of a Member, claim for funds and securities, without any transaction on the exchange will not be accepted by the relevant Committee of the Exchange as per the approved norms.
Check the frequency of accounts settlement opted for. If you have opted for running account, please ensure that your broker settles your account and, in any case, not later than once in 90 days (or 30 days if you have opted for 30 days settlement). In case of declaration of trading member as defaulter, the claims of clients against such defaulter member would be subject to norms for eligibility of claims for compensation from IPF to the clients of the defaulter member. These norms are available on Exchange website at following link: https://www.nseindia.com/invest/about-defaulter-section.
Brokers are not permitted to accept transfer of securities as margin. Securities offered as margin/ collateral MUST remain in the account of the client and can be pledged to the broker only by way of ‘margin pledge’, created in the Depository system. Clients are not permitted to place any securities with the broker or associate of the broker or authorized person of the broker for any reason. Broker can take securities belonging to clients only for settlement of securities sold by the client.
Always keep your contact details viz. Mobile number/Email ID updated with the stock broker. Email and mobile number is mandatory and you must provide the same to your broker for updation in Exchange records. You must immediately take up the matter with Stock Broker/Exchange if you are not receiving the messages from Exchange/Depositories regularly.
Don't ignore any emails/SMSs received from the Exchange for trades done by you. Verify the same with the Contract notes/Statement of accounts received from your broker and report discrepancy, if any, to your broker in writing immediately and if the Stock Broker does not respond, please take this up with the Exchange/Depositories forthwith.
Check messages sent by Exchanges on a weekly basis regarding funds and securities balances reported by the trading member, compare it with the weekly statement of account sent by broker and immediately raise a concern to the exchange if you notice a discrepancy.
Please do not transfer funds, for the purposes of trading to anyone, including an authorized person or an associate of the broker, other than a SEBI registered Stock broker.

Precautions for clients dealing in Options

Sharing of trading credentials i.e. login id & passwords including OTP’s is prohibited.
Trading in leveraged products like options without proper understanding could lead to losses. Please trade at your own risk.
Writing/ selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks could lead to losses.
Dealing in unsolicited tips through WhatsApp, Telegram, YouTube, Facebook, SMS, calls, etc should be avoided.
Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers should be avoided.

Awareness regarding guidelines regarding margin collection:

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge
Pay 20% upfront margin of the transaction value to trade in cash market segment
Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard
Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month

Advisory – KYC Compliance:

All investors are requested to take note that 6 KYC attributes i.e. Name, PAN, Address, Mobile Number, Email id and Income Range have been made mandatory. Investors availing custodian services will be additionally required to update the custodian details.
The last date to update KYC is on or before March 31, 2022.
Thereafter non-compliant trading accounts will be blocked for trading by the Exchange.
The non-compliant demat accounts will be frozen for debits by Depository Participant or Depository.
On submission of the necessary information to the stockbroker and updation of the same by the stockbroker in the Exchange systems and approval by the Exchange, the blocked trading accounts shall be unblocked by the Exchange on T+1 trading day.
The demat account shall be unfreezed once the investor submits the deficient KYC details and the same is captured by the depository participant in the depository system.
To ensure smooth settlement of trades, the investors are requested to ensure that both the trading and demat accounts are compliant with respect to the KYC requirement.
The investors are hereby requested to comply with the regulatory guidelines issued by Exchanges and Depositories from time to time with regard to KYC compliance and related requirements.
We do proprietary trading

Client Bank Account Details:

Sr. No	Name of Bank Account	Bank Account Number	IFSC Code
1	ASTHA CREDIT AND SECURITIES P LTD - USCNBA A/c	00620340000150	HDFC0000062

*Investors are requested to note that Stock broker Astha Credit and Securities Private Limited is permitted to receive/pay money from/to investor through designated bank accounts only named as client bank accounts. Stock broker Astha Credit and Securities Private Limited is also required to disclose these client bank accounts to Stock Exchange. Hence, you are requested to use following client bank accounts only for the purpose of dealings in your trading account with us. The details of these client bank accounts are also displayed by Stock Exchanges on their website under “Know/ Locate your Stock Broker.

1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in the investor's account. 2. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary.

Disclaimer:

Investment in the securities market is subject to market risks, read all the related documents carefully before investing.
Brokerage will not exceed SEBI prescribed limit.
Please refer to the Risk Disclosure Document issued by SEBI and go through the Rights and Obligations and Do's and Don'ts issued by Stock Exchanges and Depositories before trading on the Stock Exchanges.
For commodities derivatives please note that Commodities Derivatives are highly leveraged instruments.
Before investing in the asset class consider your investment objectives, level of experience and risk appetite carefully.
Mutual fund investments are subject to market risks, read all scheme related documents carefully. Mutual Funds are not an approved product of the Exchanges and any dispute related to this will not be dealt at Exchange platform. ACSPL is a Mutual fund distributor/s registered for Mutual Funds.

Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day......................issued in the interest of investors. We do Pro trading.

Client registration documents in Vernacular languages: Get Documents

Terms and Conditions | Privacy Policy | Investor Charter

Download the App Now!

SUDEEPPHRM IPO

About Sudeep Pharma Limited

Why To Invest in Sudeep Pharma Limited